Pharmaceuticals
Pharma - Formulators
from 4,871 today
Torrent Pharmaceuticals reported a strong 1QFY27 performance with revenue growing 55% YoY, beating estimates, and management expects growth to be driven by the India business, supported by semaglutide and in-house biosimilars, while maintaining a BUY recommendation with a target price of INR 5,600.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
